Infectious Disease

Johnson & Johnson to resume Covid-19 vaccine roll-out in Europe after EMA review

Johnson & Johnson (J&J) will resume Covid-19 vaccine roll-out in Europe following the European Medicines Agency’s (EMA) Pharmacovigilance Risk Assessment Committee (PRAC), which confirmed the overall benefit-risk profile being positive.

Airway Therapeutics’ IND application for AT-100 gets FDA acceptance to treat Covid-19

The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.

Anixa and OntoChem enter next stage of Covid-19 anti-viral therapy development

Biotechnology company Anixa Biosciences, partnered by IT and pharma solutions company OntoChem, has announced that it will enter the next stage of development of its potential anti-viral therapy for Covid-19.

US NIH-led study identifies SARS-CoV-2 virus infects cells in mouth

An international team led by researchers at the US National Institutes of Health (NIH) and the University of North Carolina at Chapel Hill have found that SARS-CoV-2 virus that causes Covid-19, infects cells in the mouth.

NIAID grants $2.5m to 12 institutes for bacteriophage therapy research

A branch of the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases (NIAID) has granted $2.5m to 12 institutes across the world for bacteriophage therapy research.

Bharat Biotech’s Phase III interim results of COVAXIN demonstrate efficacy of 81%

Biopharmaceutical company Ocugen has announced that its co-development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of COVAXIN, which is a whole virion inactivated Covid vaccine candidate.

Johnson & Johnson seeks EU approval for its COVID-19 vaccine

Janssen-Cilag International, a subsidiary of Johnson & Johnson has submitted a conditional marketing authorisation application (cMAA) to the European Medicines Agency (EMA) for its investigational single-dose Janssen COVID-19 vaccine candidate.

Oxford University commences trial on Covid-19 vaccine on children

The University of Oxford, along with three partner sites in the UK, has commenced the first trial to evaluate the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine. 

Johnson & Johnson submits EUA application for single-dose Covid-19 vaccine

Johnson & Johnson’s subsidiary Janssen Biotech has submitted an Emergency Use Authorization (EUA) application to the US Food and Drug Administration (FDA) for its investigational single-dose Janssen Covid-19 vaccine candidate.